2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

603. Lymphoid Oncogenesis: Basic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Pediatric, Young Adult, Animal Model
PAPER

3224 A functional genomics screen of human B-cell differentiation reveals convergent mechanisms of inherited childhood leukemia predisposition

Lara Wahlster, MD, PhD, Anna-Lena Neehus, PhD2, Andrew Lee, PhD3, Soumyaa Mazumder, MD4, Pardiss Mehrzad, BA5, Susan Black, BA6, Luana Miria Miria Messa7, Tanxin Liu, MSc8, Charley Wang, PhD9, Chen Weng, Ph.D10, Alexis Caulier, MD, PhD11, Jensen Pak, MS12, Mateusz Antoszewski, PhD13, Allison Zhang14, Samuel Ha15, Carmen Oleaga Quintas, PhD16, Adam J de Smith, PhD17, Vijay G Sankaran, MD, PhD18
1 Boston Children's Hospital, Boston, Massachusetts, United States
2 Boston Children's Hospital, Boston, Massachusetts, United States
3 Boston Children's Hospital, Boston, Massachusetts, United States
4 Boston Children's Hospital, Boston, Massachusetts, United States
5 Boston Children's Hospital, Boston, Massachusetts, United States
6 Boston Children's Hospital, Boston, Massachusetts, United States
7 Boston Children's Hospital, Boston, Massachusetts, United States
8 University of Southern California Keck School of Medicine, Los Angeles, United States
9 University of Southern California Keck School of Medicine, Los Angeles, United States
10 Boston Children's Hospital, Boston, Massachusetts, United States
11 Boston Children's Hospital, Boston, Massachusetts, United States
12 Boston Children's Hospital, Boston, Massachusetts, United States
13 Boston Children's Hospital, Boston, Massachusetts, United States
14 Boston Children's Hospital, Boston, Massachusetts, United States
15 Boston Children's Hospital, Boston, Massachusetts, United States
16 Boston Children's Hospital, Boston, Massachusetts, United States
17 University of Southern California Keck School of Medicine, Los Angeles, United States
18 Boston Children's Hospital, Boston, Massachusetts, United States

The development of preventative approaches for childhood B-cell acute lymphoblastic leukemia (B-ALL) is dependent on a deeper understanding of the mechanisms predisposing children to acquire this malignancy. Although a heritable component of B-ALL pathogenesis is increasingly recognized, how inherited risk variants promote leukemia development remains poorly understood. A major challenge to studying these has been the lack of model systems that faithfully capture the transient developmental states in which predisposition alleles act. To address this gap, we employ a semi-synchronous human in vitro B-cell differentiation platform from hematopoietic stem and progenitor cells that recapitulates early B-lymphopoiesis, and enriches for rare developmental intermediates. Flow cytometry, B-cell receptor and single-cell transcriptomic profiling confirmed a continuum of early B-cell development, including lymphoid-primed progenitors. The platform enabled enrichment of rare transitional populations from 6.3% in primary bone marrow to 98.3% of cultured cells, while maintaining transcriptional similarity, progressive RAG1 and RAG2 expression, and polyclonal immunoglobulin rearrangement.


To decipher how inherited variation alters B-cell development, we used CRISPR/Cas9 to model mutations in 9 genes selected for their established association with familial B-ALL: CDKN2A, ETV6, IKZF1, NBN, PAX5, SH2B3, TCF3, TP53, and USP9X. Two validated single-guide RNAs were used per target, with AAVS1-targeting controls. Following 3 weeks of in vitro B-cell culture, flow cytometric analyses revealed marked reductions in CD19+ B-cell output after disruption of IKZF1, PAX5, and TCF3. Several other perturbations did not alter overall CD19+ output, suggesting that subtle developmental alterations could not be resolved by bulk phenotyping alone. To investigate these effects at higher resolution, we applied multiplexed single-cell transcriptomic profiling using an arrayed single-cell CRISPR screen with cell hashing. We obtained transcriptomic data from 50,248 cells, revealing reproducible, perturbation-specific differentiation bottlenecks that varied by genetic locus. PAX5 disruption caused a strong block at early B-lineage commitment, while IKZF1 perturbations caused either a partial early lymphoid block or near-complete collapse of the B-cell trajectory. Importantly, CDKN2A, ETV6, and SH2B3 perturbations largely preserved overall CD19+ output, but showed stage-restricted depletion around the small pre-B-cell state. Although downstream transcriptional changes were perturbation-specific, the developmental alterations converged functionally on impaired progression through early B-cell states characterized by high-level RAG1 and RAG2 expression and activity. 

Because structural driver mutations in B-ALL are known to arise through off-target RAG-mediated  recombination, we hypothesized that developmental stalling at RAG-active stages increases the opportunity for these events to occur. To assess this, we analyzed paired germline and tumor whole-genome sequencing data from 1,491 children with B-ALL. Among 26,464 deletions, 71.38% contained a full recombination signal sequence at one or both breakpoints, including 43.26% outside the immunoglobulin and T-cell receptor loci. Cases harboring pathogenic or likely pathogenic germline predisposition variants exhibited RAG-associated structural alterations at frequencies comparable to cases without known germline predisposition, suggesting that predisposition likely facilitates cells remaining in vulnerable developmental stages characterized by active RAG function. 

This study establishes a human B-cell differentiation platform that enables functional interrogation of germline B-ALL predisposition alleles during early lymphopoiesis. By linking genetic perturbations to differentiation alterations at single-cell resolution, we reveal convergent developmental bottlenecks and provide a framework for variant-to-function mapping in leukemia predisposition. Our findings demonstrate that diverse predisposition genes converge on recurrent delays in early B-cell differentiation at stages with high-level RAG activity. These data support a model in which prolonged residence within these vulnerable developmental states increases the opportunity to acquire leukemogenic rearrangements and underscore the power of integrating functional genomics with developmental hematopoiesis to decode inherited leukemia risk.

Lara Wahlster, MD, PhD: No relevant conflicts of interest to declare.